Document is current
Any future updates will be listed below
-
Authors
Porper, Keren https://orcid.org/0000-0003-0734-7536
Shpatz, Yael
Plotkin, Luba
Pechthold, Ronit Goldman
Talianski, Alisa
Champ, Colin E.
Furman, Orit
Shimoni-Sebag, Ariel
Symon, Zvi
Amit, Uri
Hemi, Rina
Kanety, Hannah
Mardor, Yael
Cohen, Zvi R.
Jan, Elisheva
Genssin, Hili
Anikster, Yair
Zach, Leor
Lawrence, Yaacov R. https://orcid.org/0000-0002-9959-2485
-
Funding
Funding for this research was provided by:
Rosetrees Trust (CM209)
- License Information
-
More Information
Article History
Received: 8 May 2021
Accepted: 8 June 2021
First Online: 21 June 2021
Declarations
:
: Yaacov Lawrence: Research funding: Karyopharm Therapeutics, Checkmate Pharmaceuticals, Bristol-Myers Squibb and pending from Merck Serono. Honoria/consultancy fees: Bristol-Myers Squibb, Clinigen Group and Roche Genetech. Stock ownership: Protean Biodiagnostics Inc. Colin E. Champ receives compensation for his dietary books, Leor Zach is an advisor of Trail-IN Pharma. Scientific advisory board for Atkins, and scientific advisory board for Biosense. The other authors declare that they have no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. The trial was approved by the local Institutional Review Board (IRB) - SMC 0712 − 13, and registered on Clinicaltrials.gov NCT02149459.
: All patients signed an IRB approved informed consent form, in accordance with the principals of Good Clinical Practice (GCP).
